Tyrosinemia Type 2: A Patient Guide
At a Glance
Tyrosinemia Type 2 is managed primarily with a lifelong, carefully prescribed diet that limits natural protein and uses specialized medical formula. Controlling tyrosine levels can relieve painful eye and skin symptoms and may reduce the risk of developmental problems.
Tyrosinemia Type 2, also known as Richner-Hanhart syndrome, is an exceptionally rare genetic condition that fundamentally changes how your child’s body processes protein. In a healthy body, an enzyme called tyrosine aminotransferase acts as a specialized tool to break down an amino acid called tyrosine, which is found in most protein-rich foods [1]. For children with this condition, that tool is missing or broken due to changes in the TAT gene, causing tyrosine to build up to high levels in the blood and tissues [2]. Because the body cannot clear this buildup on its own, the excess tyrosine eventually forms crystals that irritate and damage the eyes and skin, and can increase the risk of neurological or developmental delays [3].
The condition is defined by a “triad” of symptoms that can appear at different times throughout early childhood. The first sign is often intense eye pain and light sensitivity caused by tyrosine crystals on the cornea, which are frequently and incorrectly treated as viral infections like herpes simplex [4]. Over time, painful, thickened patches of skin—known as palmoplantar hyperkeratosis—may develop on the palms of the hands and the soles of the feet, making daily activities and walking difficult [5]. Perhaps most critically, if tyrosine levels remain high and untreated, the central nervous system can be affected, leading to intellectual disabilities or permanent developmental delays [6]. It is important to know that neurological involvement is a variably reported complication, not an inevitability, and early treatment reduces this risk.
Managing Tyrosinemia Type 2 requires a precise, lifelong approach to nutrition that serves as the primary medical treatment. By strictly limiting natural protein according to a metabolic dietitian’s prescription and using a specialized medical formula that provides essential nutrients without tyrosine, parents can effectively lower blood levels and stop the cycle of crystal formation [7]. It is vital to note that while some medications, like nitisinone, are lifesaving for other forms of tyrosinemia, they are not standard treatment for Type 2 and can actually make symptoms worse by further raising tyrosine [8]. The focus remains entirely on dietary control, which offers a powerful way to support your child’s physical comfort and cognitive future.
While the diagnosis of such a rare condition is life-changing, the path forward is one of active management with your care team. When the diet is maintained and tyrosine levels are kept within a safe range, the painful eye and skin symptoms often improve substantially or resolve completely, sometimes within just a few weeks [2]. By working closely with a metabolic care team, families can provide their children with the stability they need to meet their milestones. The diet is demanding, and occasionally dealing with fluctuating levels or needing help does not represent a parental failure [7].
In this guide
6 chapters
Understanding Tyrosinemia Type 2: An Overview for Parents
Learn how Tyrosinemia Type 2 affects children, why TAT gene changes matter, and how a low-tyrosine diet, formula, and monitoring support healthy development.
Recognizing Symptoms and Warning Signs
Learn about Tyrosinemia Type 2 symptoms, including eye irritation, painful skin changes, developmental changes, and urgent warning signs in affected children.
Confirming the Diagnosis: Understanding the Tests
Learn how tyrosinemia type 2 is diagnosed, including plasma amino acids, succinylacetone and TAT gene testing, HSV-like symptoms, and newborn screening limits.
Managing the Condition Through Diet
Learn how to manage Tyrosinemia Type 2 with prescribed protein limits, medical formula, blood tests, symptom relief, and sick-day planning for caregivers.
Monitoring and Long-Term Outlook
Learn how Tyrosinemia Type 2 is monitored over time, including blood tests, eye exams, developmental checks, diet adherence, and long-term outlook for children.
Building Your Care Team and Preparing for Visits
Learn how to build a Tyrosinemia Type 2 care team, prepare records and diet logs, and plan questions, monitoring, and sick-day support for clinic visits.
Common questions in this guide
What causes Tyrosinemia Type 2?
What symptoms can Tyrosinemia Type 2 cause in a child?
How is Tyrosinemia Type 2 treated?
Is nitisinone used to treat Tyrosinemia Type 2?
Can the eye and skin symptoms get better with treatment?
How can families manage the dietary needs at home and school?
Get notified when new evidence is published on Tyrosinemia type 2.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (8)
- 1
Characteristics, tissue-specific expression, and hormonal regulation of expression of tyrosine aminotransferase in the avian female reproductive tract.
Lim W, Song G
Domestic animal endocrinology 2016; (57()):10-20.
PMID: 27295280 - 2
Tyrosinemia type II: Mutation update, 11 novel mutations and description of 5 independent subjects with a novel founder mutation.
Peña-Quintana L, Scherer G, Curbelo-Estévez ML, et al.
Clinical genetics 2017; (92(3)):306-317 doi:10.1111/cge.13003.
PMID: 28255985 - 3
Herpetiform keratitis and palmoplantar hyperkeratosis: warning signs for Richner-Hanhart syndrome.
Soares DC, Stroparo MN, Lian YC, et al.
Journal of inherited metabolic disease 2017; (40(3)):461-462 doi:10.1007/s10545-016-9996-z.
PMID: 27832414 - 4
An Infant with Bilateral Keratitis: From Infectious to Genetic Diagnosis.
Thibault LP, Mitchell GA, Parisien B, et al.
The American journal of case reports 2022; (23()):e937967 doi:10.12659/AJCR.937967.
PMID: 36447403 - 5
Bilateral dendriform ulcer leading to an early diagnosis of tyrosinemia type 2.
Martin GC, de Lonlay P, Chapron T, et al.
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 2020; (24(2)):120-122 doi:10.1016/j.jaapos.2019.12.007.
PMID: 32018000 - 6
Tyrosinemia type II: Novel mutations in TAT in a boy with unusual presentation.
Gokay S, Kendirci M, Ustkoyuncu PS, et al.
Pediatrics international : official journal of the Japan Pediatric Society 2016; (58(10)):1069-1072 doi:10.1111/ped.13062.
PMID: 27285949 - 7
[Screening for hereditary tyrosinemia and genotype analysis in newborns].
Tong F, Yang R, Liu C, et al.
Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 2019; (48(4)):459-464 doi:10.3785/j.issn.1008-9292.2019.08.18.
PMID: 31901053 - 8
Predicting tyrosinaemia: a mathematical model of 4-hydroxyphenylpyruvate dioxygenase inhibition by nitisinone in rats.
Ward JP, Dunster JL, Derks G, et al.
Mathematical medicine and biology : a journal of the IMA 2017; (34(3)):335-390 doi:10.1093/imammb/dqw006.
PMID: 27305933
This page is for informational purposes only and does not constitute medical advice about your child’s Tyrosinemia Type 2. A metabolic specialist and dietitian should guide protein restriction, medical formula, and monitoring.